Showing results (91-100 of 100) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed NeuroblastomaJane Carr-Wilkinson, Kieran O'Toole, Katrina M Wood, et al.European Journal of Cancer (Oxford, England : 1990)|October 15, 2010
Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium StudyBirgit Geoerger, Julia Chisholm, Marie-Cecile Le Deley, et al.Hemasphere|June 5, 2023
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study ProtocolCarmelo Rizzari, Anja Möricke, Maria Grazia Valsecchi, et al.Eclinicalmedicine|December 17, 2024
Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trialEwa Koscielniak, Gustaf Ljungman, Bernarda Kazanowska, et al.Cancer Medicine|May 27, 2016
Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007Kerstin Bartelheim, Karolina Nemes, Angela Seeringer, et al.Blood|February 21, 2008
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95Anja Möricke, Alfred Reiter, Martin Zimmermann, et al.Haematologica|February 2, 2019
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 studyCarmelo Rizzari, Claudia Lanvers-Kaminsky, Maria Grazia Valsecchi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized StudyValentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.Journal of Cancer Research and Clinical Oncology|March 7, 2019
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002Alexander Karachunskiy, Gesche Tallen, Julia Roumiantseva, et al.Neuro-Oncology|December 29, 2019
Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumorsMichael C Frühwald, Martin Hasselblatt, Karolina Nemes, et al.Pageof 10